西藏藥業(600211.SH)及控股子公司2021年度擬向銀行申請合計餘額不超15億元綜合授信額度
格隆匯 3 月 11日丨西藏藥業(600211.SH)公佈,根據公司資金需求,公司及控股子公司(諾迪康醫藥、諾迪康生物和欣活生物)在2021年度擬向銀行申請合計餘額不超過15億元人民幣綜合授信額度(不包括前期已辦理的授信額度),其中控股子公司的授信額度不超過13億元。在期限內(即公司2020年年度股東大會召開日至2021年年度股東大會召開日),該授信額度可以在授權範圍內循環使用,具體銀行授信額度、授信類型以及與之配套的擔保、抵押、質押事項,以公司及控股子公司與相關銀行簽訂的協議為準。公司將根據實際經營需要在授信額度內向合作銀行申請融資,以隨時滿足公司未來經營發展的融資需求。
公司將根據實際情況及銀行可能提出的要求,為控股子公司在上述授信額度範圍內項下所產生的全部債務提供連帶責任擔保(擔保方式包括但不限於保證、抵押和質押等),被擔保控股子公司以其相應資產向公司提供反擔保。同時,公司授權董事長或其授權代表簽署相關授信合同及與之配套的擔保、資產抵押、質押等其他相關法律文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.